Grantham, Mayo, Van Otterloo & Co (GMO)
EGRX

Grantham, Mayo, Van Otterloo & Co (GMO)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,600
Closed -$258K – 842
2020
Q1 		$258K Buy
+5,600
New +$281K ﹤0.01% 677

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s EGRX Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 5,600 shares — an estimated $258K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in EGRX in Q1 2020 and held it in 1 quarter. The position peaked at $258K in Q1 2020. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 5,600 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $258K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Eagle Pharmaceuticals, Inc. position peaked at $258K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.